Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Plat-E: an efficient and stable system for transient packaging of retroviruses

MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898

Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 754

B cells acquire antigen from target cells after synapse formation

Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526

CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner

Lo, J. W., Schroeder, J.-H., Beattie, G., Roberts, L. B., Cozzetto, D., Omer, O., Ross, E. M., Heuts, F. W. H., Jowett, G. M., Read, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51719-6 · Cited by 21

Neonatal Mucosal Immune Stimulation by Microbial Superantigen Improves the Tolerogenic Capacity of CD103+ Dendritic Cells

Stern, A., Wold, A. E., & Östman, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075594 · Cited by 19

Sequential Induction of Effector Function, Tissue Migration and Cell Death during Polyclonal Activation of Mouse Regulatory T-Cells

Langenhorst, D., Gogishvili, T., Ribechini, E., Kneitz, S., McPherson, K., Lutz, M. B., & Hünig, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050080 · Cited by 19

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease

Flies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 18

CTLA‐4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T‐cell priming in arthritis

Klocke, K., Holmdahl, R., & Wing, K. (2017) · Immunology · doi:10.1111/imm.12754 · Cited by 19

Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy

Erkers, T., Stikvoort, A., & Uhlin, M. (2017) · Stem Cells International · doi:10.1155/2017/5738371 · Cited by 19

New insights on T-cell self-tolerance

Yi, J., Kawabe, T., & Sprent, J. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.10.002 · Cited by 19

Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy

D’Andrea, M. A., & Reddy, G. K. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000651 · Cited by 19

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model

Rodríguez-Barbosa, J.-I., Azuma, M., Zelinskyy, G., Pérez‐Simón, J. A., & del Rio, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02520-z · Cited by 18

Immunomodulatory Strategies Targeting Dendritic Cells to Improve Corneal Graft Survival

Schönberg, A., Hamdorf, M., & Bock, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051280 · Cited by 19

Functional Heterogeneity and Therapeutic Targeting of Tissue-Resident Memory T Cells

van der Gracht, E. T. I., Behr, F. M., & Arens, R. (2021) · Cells · doi:10.3390/cells10010164 · Cited by 22

T-Cell Costimulatory Blockade in Organ TransplantationPreprint

Maltzman, J. S., & Turka, L. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015537 · Cited by 18

Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis

de Kivit, S., Mensink, M., Kostidis, S., Derks, R. J. E., Zaal, E. A., Heijink, M., Verleng, L. J., de Vries, E., Schrama, E., Blomberg, N., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114681 · Cited by 23

The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies

Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19

Conversion of pathogenic T cells into functionally stabilized T reg cells for antigen-specific immunosuppression in pemphigus vulgaris

Mukai, M., Takahashi, H., Kubo, Y., Asahina, Y., Iriki, H., Nomura, H., Kamata, A., Ito, H., Kurebayashi, Y., Yamagami, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq9913 · Cited by 19

Selective Costimulation Blockade With Antagonist Anti-CD28 Therapeutics in Transplantation

Vanhove, B., Poirier, N., Soulillou, J., & Blancho, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002740 · Cited by 18

Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens

Uraki, R., Imai, M., Ito, M., Shime, H., Odanaka, M., Okuda, M., Kawaoka, Y., & Yamazaki, S. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010085 · Cited by 18

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Wang, F., Xia, T., Li, Z., Gao, X., & Fang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213297 · Cited by 19

Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation

Toskov, V., & Ehl, S. R. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00167-1 · Cited by 19

Foxp3-mediated blockage of ryanodine receptor 2 underlies contact-based suppression by regulatory T cells

Wang, X., Geng, S., Meng, J., Kang, N., Liu, X.-Y., Xu, Y., Lyu, H., Xu, Y., Xu, X., Song, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163470 · Cited by 18

Fish Uses CTLA-4 Immune Checkpoint to Suppress mTORC1-Controlled T-Cell Glycolysis and Immunity

Zhang, J., Wei, X., Zhang, Q., Jiao, X., Li, K., Geng, M., Cao, Y., Wang, D., Cheng, J., & Yang, J. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300599 · Cited by 17

CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs

Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45625-0 · Cited by 18

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets

Vilela, T., Valente, S., Correia, J., & Ferreira, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189144 · Cited by 19

Immune‐related adverse events of antibody‐based biological medicines in cancer therapy

Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 20

New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine

Gojo, I., & Karp, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0900 · Cited by 18

Management of intracranial melanomas in the era of precision medicine

Young, G. J., Bi, W. L., Wu, W. W., Johanns, T. M., Dunn, G. P., & Dunn, I. F. (2017) · Oncotarget · doi:10.18632/oncotarget.19223 · Cited by 18

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2018) · Biomedicines · doi:10.3390/biomedicines6010026 · Cited by 18

Cell-mediated immune resistance in cancer

Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 20

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1

Hao, Y., & Cook, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806043 · Cited by 21

The new quest in CTLA-4 insufficiency: How to immune modulate effectively?

Westermann-Clark, E., Ballow, M. C., & Walter, J. E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.020 · Cited by 18

PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration

Kantheti, U., Forward, T. S., Lucas, E. D., Schafer, J. B., Tamburini, P. J., Burchill, M. A., & Tamburini, B. A. J. (2025) · Science Advances · doi:10.1126/sciadv.adt3044 · Cited by 17

Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

Tuyết, N. T., & Youn, Y. S. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202426047 · Cited by 17

Chemokines: humble yet mighty players in the tumour microenvironment

Xavier, H., Moly, A. G. G., Thomas, J. A., Suboj, P., Suresh, A., Biju, E., Baby, A., Dominic, R. T., & Babykutty, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601756 · Cited by 17

Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders

Vanhove, B., Poirier, N., Fakhouri, F., Laurent, L., Hart, B. A. ‘., Papotto, P. H., Rizzo, L. V., Zaitsu, M., Issa, F., Wood, K. J., et al. (2017) · Antibodies · doi:10.3390/antib6040019 · Cited by 16

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency

Yang, L., Xue, X., Chen, X., Wu, J., Yang, X., Xu, L., Tang, X., Wang, M., Mao, H., & Zhao, X. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.03.001 · Cited by 17

Progress in research into the role of abnormal glycosylation modification in tumor immunity

Liu, H., Ma, L., Cao, B., Lin, J., Han, L., Li, C., Xu, R., & Zhang, D. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.11.003 · Cited by 17

In Situ Micro–Nano Conversion Augmented Tumor-Localized Immunochemotherapy

Sun, S., Tang, Q., Wang, Y., Zhang, L., Chen, J., Xu, M., Sun, L., Cui, L., & Liang, X. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02490 · Cited by 17

The role of regulatory T cells and follicular T helper cells in HBV infection

Lin, N., Yin, W. H., Miller, H. I., Byazrova, M. G., Herrada, A. A., Benlagha, K., Lee, P. P. W., Guan, F., Lei, J., Gong, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1169601 · Cited by 20

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Mukherjee, D., Romano, E., Walshaw, R. C., Zeef, L. A. H., Banyard, A., Kitcatt, S. J., Cheadle, E. J., Tuomela, K., Pendharkar, S., Al-Deka, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2223094 · Cited by 17

Research progress of CD80 in the development of immunotherapy drugs

Li, L., Yang, L., & Jiang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1496992 · Cited by 19

CD4+Foxp3+ Tregs protect against innate immune cell-mediated fulminant hepatitis in mice

Hou, X., Song, J., Su, J., Huang, D., Gao, W., Yan, J., & Shen, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.015 · Cited by 17

The predominance of a naive T helper cell subset in the immune response of experimental acute pancreatitis

Schmidt, A., Kühlbrey, C. M., Lauch, R., Wolff-Vorbeck, G., Chikhladze, S., Hopt, U. T., & Wittel, U. A. (2017) · Pancreatology · doi:10.1016/j.pan.2017.02.011 · Cited by 17

Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma

Lucca, L. E., & Hafler, D. A. (2017) · Immunological Reviews · doi:10.1111/imr.12529 · Cited by 18

Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity

Hou, T. Z., Olbrich, P., Soto, J. M. L., Sánchez, B., Moreno, P. S., Borte, S., Stauss, H. J., Burns, S. O., Walker, L. S. K., Pan‐Hammarström, Q., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.01.001 · Cited by 17

Belatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results

Schwarz, C. C., Mahr, B., Muckenhuber, M., & Wekerle, T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1485489 · Cited by 17

Mechanisms of polarized cell-cell communication of T lymphocytes

Torralba, D., Martin-Cofreces, N. B., & Sánchez‐Madrid, F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.009 · Cited by 17

Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Play a Major Role in CD4+ T-Cell Impairment During Sepsis

Gaborit, B. J., Roquilly, A., Louvet, C., Sadek, A., Tessoulin, B., Broquet, A. H., Jacqueline, C., Vourc’h, M., Chaumette, T., Chauveau, M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa225 · Cited by 17

Inhibition of acid sphingomyelinase increases regulatory T cells in humans

Wiese, T., Dennstädt, F., Hollmann, C., Stonawski, S., Wurst, C., Fink, J., Gorte, E., Mandasari, P., Domschke, K., Hommers, L. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab020 · Cited by 17

In vivo Treg expansion under costimulation blockade targets early rejection and improves long-term outcome

Schwarz, C. C., Mahr, B., Muckenhuber, M., Weijler, A. M., Unger, L. W., Pilat, N., Latus, M., Regele, H. M., & Wekerle, T. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16724 · Cited by 16

A reasoned approach to the treatment of autoimmune hepatitis

Vergani, D., Beretta‐Piccoli, B. T., & Mieli‐Vergani, G. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.033 · Cited by 17

Hijacking Sexual Immuno-Privilege in GBM—An Immuno-Evasion Strategy

Sharpe, M. A., Baskin, D. S., Jenson, A. V., & Baskin, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010983 · Cited by 17

Innate Lymphoid Cells: Role in Immune Regulation and Cancer

Chung, D. C., Jacquelot, N., Ghaedi, M., Warner, K., & Ohashi, P. S. (2022) · Cancers · doi:10.3390/cancers14092071 · Cited by 17

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy

Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17

The Efficacy of Abatacept in Reducing Synovial T Cell Activation by CD1c Myeloid Dendritic Cells Is Overruled by the Stimulatory Effects of T Cell–Activating Cytokines

van Vliet-Moret, F. M., Bijlsma, J. W. J., Lafeber, F. P. J. G., & van Roon, J. A. G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38982 · Cited by 17

Conditions for the generation of cytotoxic CD4 + Th cells that enhance CD8 + CTL‐mediated tumor regression

Li, K., Baird, M. A., Yang, J., Jackson, C., Ronchese, F., & Young, S. L. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.46 · Cited by 17

Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease

Feng, T., Zou, T., Wang, X., Zhao, W., & Qin, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i21.3832 · Cited by 17

Toxicité des inhibiteurs de points de contrôle immunitaires

Delaunay, M., Caron, P. J., Sibaud, V., Godillot, C., Collot, S., Milia, J., Prévôt, G., & Mazières, J. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.08.006 · Cited by 17

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives

Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17

Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) – protocol for a multi-center, single-arm phase IIa trial

Frye, B. C., Rump, I. C., Uhlmann, A., Schubach, F., Ihorst, G., Grimbacher, B., Zissel, G., & Quernheim, J. M. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100575 · Cited by 18

CTLA-4—two pathways to anti-tumour immunity?

Ward, F. J., Kennedy, P. T., Al-Fatyan, F., Dahal, L. N., & Eid, R. A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf008 · Cited by 16

Cardiovascular adverse effects of immunotherapy in cancer: insights and implications

Du, H., Wang, J., & Wang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1601808 · Cited by 19

Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody

Gao, H. J., Cai, H., Liu, J., Wang, X., Zheng, P., Devenport, M., Xu, T., Dou, F., Liu, Y., & Zhou, A. (2020) · Cell Discovery · doi:10.1038/s41421-020-00202-9 · Cited by 18

Role and Function of Regulatory T Cell in Chronic Rhinosinusitis with Nasal Polyposis

Lei, C., Jiang, J., Zhang, Y., & Xiong, G. (2022) · Journal of Immunology Research · doi:10.1155/2022/1144563 · Cited by 16

Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review

Wang, H., Qian, Y., Dong, H., & Cong, W. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-527 · Cited by 19

Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development

Kim, T., Martínez‐Bonet, M., Wang, Q., Hackert, N. S., Sparks, J. A., Baglaenko, Y., Koh, B., Darbousset, R., Briviesca, R. L., Chen, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46457-8 · Cited by 17

Visualized photodynamic nanomaterials activating tumor-associated immune landscape as a next-generation anticancer strategy

Tian, L., Li, X., Guo, L., Huang, L., Wu, X., & Gao, W. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216027 · Cited by 16

Rapid turnover of CTLA4 is associated with a complex architecture of reversible ubiquitylation

Tey, P. Y., Dufner, A., Knobeloch, K., Pruneda, J. N., Clague, M. J., & Urbé, S. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202312141 · Cited by 20

Tyrosine 201 of the cytoplasmic tail of CTLA ‐4 critically affects T regulatory cell suppressive function

Stumpf, M., Zhou, X., Chikuma, S., & Bluestone, J. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201343891 · Cited by 16

Exploring intercellular signaling by proteomic approaches

Tian, R. (2013) · PROTEOMICS · doi:10.1002/pmic.201300259 · Cited by 17

New anticancer immunotherapies.

Franks, H., Wang, Q., & Patel, P. M. (2012) · PubMed · Cited by 16

Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance

Matheu, M. P., Su, Y. A., Greenberg, M. L., Blanc, C. A., Parker, I., Scott, D. W., & Cahalan, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205150109 · Cited by 16

Immune checkpoint pathways in non-small cell lung cancer

Chae, Y. K., Arya, A., Iams, W. T., Cruz, M., Mohindra, N. A., Villaflor, V. M., & Giles, F. J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.30 · Cited by 16

Regulatory T cells demonstrate significantly increased functions following stimulation with IL-2 in a Tim-3-dependent manner in intracranial aneurysms

Zhang, H., Liang, G., Zhao, M., Zhao, G.-F., & Luo, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.029 · Cited by 16

Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis

Abdelhafeez, A. A. M., Shohdy, K. S., & Ibrahim, W. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1714053 · Cited by 16

Rap1 prevents colitogenic Th17 cell expansion and facilitates Treg cell differentiation and distal TCR signaling

Ishihara, S., Sato, T., Fujikado, N., Miyazaki, H., Yoshimoto, T., Yamamoto, H., Fukuda, S., & Katagiri, K. (2022) · Communications Biology · doi:10.1038/s42003-022-03129-x · Cited by 18

Comparison of the Intracellular Trafficking Itinerary of CTLA-4 Orthologues

Kaur, S., Qureshi, O., & Sansom, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060903 · Cited by 16

Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma

Coventry, B. J., Lilly, C. A., Hersey, P., Michele, A., & Bright, R. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-9 · Cited by 15

CD25-expressing Th17 cells mediate CD8+ T cell suppression in CTLA-4 dependent mechanisms in pancreatic ductal adenocarcinoma

Lang, C., Wang, J., & Chen, L. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.030 · Cited by 16

Cytotoxic T-Lymphocyte-Associated Protein 4 Haploinsufficiency-Associated Inflammation Can Occur Independently of T-Cell Hyperproliferation

Coz, C. L., Nolan, B. E., Trofa, M., Kamsheh, A. M., Khokha, M. K., Lakhani, S. A., Novelli, A., Zackai, E. H., Sullivan, K. E., Briuglia, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01715 · Cited by 16

Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells

Hou, T. Z., Qureshi, O., & Sansom, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-8938-6_7 · Cited by 16

Induction of CD137 expression by viral genes reduces T cell costimulation

Wu, M., Wong, H. Y., Lin, J. L., Moliner, A., & Schwarz, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28710 · Cited by 16

Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer

Bess, S. N., Greening, G. J., & Muldoon, T. J. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.10.002 · Cited by 16

RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy

Zhigalova, E., Izosimova, A. V., Yuzhakova, D. V., Volchkova, L. N., Shagina, I. A., Turchaninova, M. A., Serebrovskaya, E. O., Вадимовна, З. Е., Chudakov, D. M., & Sharonov, G. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00385 · Cited by 17

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease

Seethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Li, Y., Wang, S., Lin, M., Hou, C., Li, C., & Li, G. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0927-0 · Cited by 15

The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies

Sadeghi, M. R., Khodakarami, A., Ahmadi, A., Fathi, M., Navashenaq, J. G., Mohammadi, H., Yousefi, M., Hojjat‐Farsangi, M., Akbari, A. A. M., & Jadidi‐Niaragh, F. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2170781 · Cited by 15

Radiation Skin Injury Care in Radiotherapy for Oncology: Mechanisms, Drug Therapy and Novel Biomaterial Application Strategies

Wang, Y., Yang, L., Liu, B., Liao, S., Fu, X., Zhou, Y., & Zhou, P. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300024 · Cited by 15

Systems immunology of regulatory T cells: can one circuit explain it all?

Tripathi, S., Tsang, J. S., & Park, K. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.08.007 · Cited by 15

Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?

Amini, L., Kaeda, J., Weber, O., & Reinke, P. (2024) · Transplantation · doi:10.1097/tp.0000000000004866 · Cited by 15

Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment

Ren, Z., Yang, K., Zhu, L. D., Yin, D., & Zhou, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111934 · Cited by 15

The function of sub‐synaptic vesicles during T‐cell activation

Purbhoo, M. A. (2012) · Immunological Reviews · doi:10.1111/imr.12012 · Cited by 15

Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation

Pilat, N., Schwarz, C. C., & Wekerle, T. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328355fc94 · Cited by 15

Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals

Kim, M. T., Kurup, S. P., Starbeck-Miller, G. R., & Harty, J. T. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600641 · Cited by 15

Precision medicine in the treatment of primary immunodeficiency diseases

Leiding, J. W., & Ballow, M. C. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000431 · Cited by 15

Induction of co-inhibitory molecule CTLA-4 by human papillomavirus E7 protein through downregulation of histone methyltransferase JHDM1B expression

Zhou, Q., Chen, L., Song, Y., Ma, L., Xiao, P., Chen, L., Zhen, H., Han, R., Chen, X., Sun, S., et al. (2019) · Virology · doi:10.1016/j.virol.2019.10.001 · Cited by 15

The role of trogocytosis in immune surveillance of Hodgkin lymphoma

Zeng, Q., & Schwarz, H. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781334 · Cited by 15

Higher Frequency and Increased Expression of Molecules Associated with Suppression on T Regulatory Cells from Newborn Compared with Adult Nonhuman Primates

Holbrook, B. C., & Alexander‐Miller, M. A. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000461 · Cited by 15

Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer

Ding, P., Wen, L., Tong, F., Zhang, R., Huang, Y., & Dong, X. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.104 · Cited by 15

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab

Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16

Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions

Fathi, M., Razavi, S., Sojoodi, M., Ahmadi, A., Ebrahimi, F., Namdar, A., Hojjat‐Farsangi, M., Gholamin, S., & Jadidi‐Niaragh, F. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2160703 · Cited by 15

CTLA-4-mediated trans-endocytosis in the control of T cell co-stimulation

Ovcinnikovs, V. (2018) · UCL Discovery (University College London)

Investigating transendocytosis mediated by CTLA4

Nguyen, L. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24962

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 56

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 227

Molecular and Cellular Functions of CTLA-4

Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 259